Abstract The development of cisplatin resistance often results in a grim prognosis in advanced or recurrent bladder cancer.However, effective treatment strategies for cisplatin resistance have not been well established.Herein, we found that overactivation of SRC is associated with cisplatin-resistance.SRC activates hexokinase2 which up-regulates glycolysis and especially the pentose phosphate pathway that leading to increased nucleotide synthesis and NADPH production which Course a pied - Accessoires - Casquettetuque can neutralize reactive oxygen species (ROS) induced by cisplatin, thereby protecting bladder cancer cells from cisplatin-induced DNA damage.
This phenomenon was effectively reversed by knockout of SRC and inhibition of SRC activity by the SRC inhibitor, eCF506.Moreover, we constructed Cell-derived xenograft (CDX) and Patient-derived xenograft (PDX) from cisplatin-resistant bladder cancer patient.eCF506 exhibited excellent anti-tumor effects and effectively enhanced cisplatin-sensitivity.Altogether, our findings demonstrate that targeting SRC is a promising approach HERBATINT 7M to overcome cisplatin-resistance in bladder cancer, and providing new insights for combination therapy in bladder cancer.